Kiadis Pharma appoints Dr. Robert Friesen as Chief Scientific Officer

Kiadis Pharma appoints Dr. Robert Friesen as Chief Scientific Officer

Amsterdam, The Netherlands, and Boston, Massachusetts, USA – February 4, 2019 – Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, today announces the appointment of Robert Friesen, PhD as Chief Scientific Officer (CSO) effective February 1, 2019. Dr. Friesen will lead the Company’s science, discovery and pre-clinical development activities and will be instrumental in building the Company’s scientific platform and identifying other programs for potential in-license. Dr. Friesen will report to Kiadis CEO Arthur Lahr and will be a member of the Company’s management team.

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH